Phase II
The Phase II trial, VLA150202, evaluated the safety and immunogenicity of VLA15 on 246 healthy adults aged 18 to 65 years old across the United States.
The initiative marks a milestone in the biopharmaceutical industry’s COVID-19 response efforts as it now seeks to protect not just those who had contracted the virus but also those who are around them.
Capricor announced positive final data from the HOPE-2 trial of its drug candidate. It showed a slowing of disease progression in Duchenne muscular dystrophy patients.
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
Study: Adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TILs) is more effective in patients who have not been treated with checkpoint inhibitors than in those who have undergone one or more therapies.
Cassava Sciences announced top-line results Wednesday from a 12-month interim analysis of its Alzheimer’s drug candidate simufilam.
On Wednesday, the company said that its adjuvanted protein-based COVID-19 vaccine candidate, dubbed SCB-2019 (CpG 1018/Alum), hit the primary and secondary efficacy endpoints in a Phase II/III clinical trial.
As the COVID-19 pandemic hit a grim milestone, marking more U.S. deaths than were reported in the 1918–19 Spanish flu pandemic, research and breakthroughs continue.
It earned the FDA’s green light after its Phase II innovaTV 204 clinical trial delivered stellar results in terms of tumor response and durability of the response.
The Phase II/III trial showed a favorable safety profile and “robust” neutralizing antibody responses in children five to 11 years old who received two 10 µg doses of the vaccine at 21 days apart.
PRESS RELEASES